Some think investing in stocks requires substantial start-up capital, but that's false. Even with a modest sum, like $40, investors can acquire shares of companies whose long-term prospects look exciting, and all for the price of a few breakfast items. As long as investors hold on to these companies' shares for a while and add to their positions regularly, strong returns await them.That said, let's discuss two stocks, each of which is trading for less than $40, that are worth investors' serious consideratio ...

Investors interested in stocks from the Medical - Biomedical and Genetics sector have probably already heard of Exelixis (EXEL) and Techne (TECH) . But which of these two stocks is more attractive to value investors? We'll need to take a closer look to find out.Everyone has their own methods for finding great value opportunities, but our model includes pairing an impressive grade in the Value category of our Style Scores system with a strong Zacks Rank. The Zacks Rank is a proven strategy that targets compa ...

Core Insights - Exelixis (EXEL) is expected to report quarterly earnings of $0.51 per share, reflecting a 54.6% increase year-over-year, with revenues forecasted at $562.88 million, a 17.4% increase from the previous year [1]. Earnings Estimates - Over the last 30 days, the consensus EPS estimate for the quarter has been revised upward by 3.3%, indicating analysts' reassessment of their initial forecasts [2]. - Changes in earnings estimates are crucial for predicting investor reactions to the stock, as empirical research shows a strong correlation between earnings estimate revisions and short-term stock price performance [3]. Revenue Projections - Analysts estimate 'Revenues- Net product' to be $505.98 million, representing a 17.9% increase from the prior-year quarter [5]. - 'Revenues- Net product- CABOMETYX' is projected to reach $501.25 million, indicating a 17.2% year-over-year change [5]. - 'Revenues- License' is expected to be $54.80 million, reflecting a 21.2% increase from the previous year [5]. - 'Revenues- Collaboration services' is forecasted at $1.94 million, which indicates a significant decline of 61.9% from the year-ago quarter [6]. Stock Performance - Exelixis shares have decreased by 2.8% over the past month, contrasting with the Zacks S&P 500 composite's increase of 2.1% [6]. - With a Zacks Rank 2 (Buy), Exelixis is anticipated to outperform the overall market in the near term [6].

Shares of Exelixis (EXEL) were down 5.13% on Jan. 24, following a downgrade in rating by analysts at Oppenheimer.Oppenheimer downgraded EXEL to “Perform” from “Outperform” as the analysts were concerned about the potential differentiation of pipeline candidate zanzalintinib versus cabozantinib following the abstract for STELLAR-001 study at American Society of Clinical Oncology 2025 Gastrointestinal Cancers Symposium (ASCO GI).While Oppenheimer believes data from STELLAR-001 likely derisk the late-stage STE ...

EnglishItalianoEspañolPortuguêsDeutschالعربيةFrançaisImportant DisclaimersThe content provided on the website includes general news and publications, our personal analysis and opinions, and contents provided by third parties, which are intended for educational and research purposes only. It does not constitute, and should not be read as, any recommendation or advice to take any action whatsoever, including to make any investment or buy any product. When making any financial decision, you should perform your ...

Investors interested in Medical - Biomedical and Genetics stocks are likely familiar with Exelixis (EXEL) and Techne (TECH) . But which of these two companies is the best option for those looking for undervalued stocks? Let's take a closer look.We have found that the best way to discover great value opportunities is to pair a strong Zacks Rank with a great grade in the Value category of our Style Scores system. The Zacks Rank favors stocks with strong earnings estimate revision trends, and our Style Scores ...

Looking for a stock that has been consistently beating earnings estimates and might be well positioned to keep the streak alive in its next quarterly report? Exelixis (EXEL) , which belongs to the Zacks Medical - Biomedical and Genetics industry, could be a great candidate to consider.When looking at the last two reports, this drug developer has recorded a strong streak of surpassing earnings estimates. The company has topped estimates by 69.47%, on average, in the last two quarters.For the last reported qu ...

Exelixis, Inc. (EXEL) announced its preliminary financial results for fiscal 2024 and provided guidance for fiscal 2025.Revenues, on a preliminary basis, for 2024 were approximately $2.165 billion, while net product revenues were $1.8 billion. The preliminary number for total revenues marginally beat the Zacks Consensus Estimate of $2.16 billion.The company also updated on its anticipated pipeline and regulatory milestones.Shares of Exelixis have surged 58.7% in a year against the industry’s decline of 16.3 ...

FDA Update on Cabozantinib sNDA - The FDA notified Exelixis about an update to its supplemental new drug application (sNDA) for cabozantinib, seeking approval for treating adults with advanced pancreatic neuroendocrine tumors (pNET) and advanced extra-pancreatic NET (epNET) [1] - The sNDA was initially scheduled for discussion at an Oncologic Drugs Advisory Committee (ODAC) meeting in March 2025 but will no longer be discussed, with a target action date of April 3, 2025 [2] - The sNDA is based on the final results of the phase III CABINET pivotal trial, which evaluated cabozantinib versus placebo in advanced pNET and epNET [11] Clinical Trial Results and Orphan Drug Designation - The CABINET trial showed substantial improvement in progression-free survival (PFS), leading to the recommendation to stop enrollment and unblind patients to allow crossover from placebo to cabozantinib [3] - Final results confirmed statistically significant and clinically meaningful improvements in PFS with cabozantinib versus placebo [8] - The FDA granted cabozantinib orphan drug designation for the treatment of pNET in August 2024 [4] Cabometyx Sales and Pipeline Expansion - Exelixis generated $1.3 billion in product revenues in the first nine months of 2024, primarily from Cabometyx sales [9] - The company is working to expand the Cabometyx label and diversify its oncology portfolio beyond Cabometyx [9] - Another promising candidate, zanzalintinib, is being evaluated in late-stage studies for metastatic refractory colorectal cancer, with preliminary results expected in 2025 [13] Collaboration with Merck - Exelixis is collaborating with Merck to evaluate zanzalintinib in combination with Keytruda for head and neck squamous cell carcinoma (HNSCC) and with Welireg for renal cell carcinoma (RCC) [5] - Merck will supply Keytruda for the phase III STELLAR-305 study in previously untreated PD-L1-positive recurrent or metastatic HNSCC [10] Stock Performance and Industry Comparison - Exelixis' shares have gained 53.2% in the past six months, outperforming the industry's decline of 10.1% [7] - The company currently carries a Zacks Rank 2 (Buy), while other top-ranked biotech stocks include Immunocore Holdings plc (IMCR) and Castle Biosciences, Inc. (CSTL), both with a Zacks Rank 1 (Strong Buy) [6]

If you like what you have just read and want to receive at least 4 exclusive stock tips every week focused on Pharma, Biotech and Healthcare, then join me at my marketplace channel, Haggerston BioHealth . Invest alongside the model portfolio or simply access the investment bank-grade financial models and research. I hope to see you there.The group is for both novice and experienced biotech investors. It provides catalysts to look out for and buy and sell ratings. It also provides product sales and forecasts ...